We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

104 hedge funds and large institutions have $737M invested in Aclaris Therapeutics in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 54 increasing their positions, 24 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,097% more call options, than puts

Call options by funds: $4.24M | Put options by funds: $354K

125% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 24

10.48% more ownership

Funds ownership: 95.81% → 106.29% (+10%)

6% more capital invested

Capital invested by funds: $694M → $737M (+$42.2M)

0% more funds holding

Funds holding: 104 → 104 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
104
Holders Change
–
Holders Change %
0%
% of All Funds
2.59%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
12
Increased
54
Reduced
24
Closed
12
Calls
$4.24M
Puts
$354K
Net Calls
+$3.88M
Net Calls Change
+$81K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$32.2M
2
BlackRock
BlackRock
New York
+$13.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$9.96M
4
FCMI
Foresite Capital Management III
California
+$7.05M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.94M

Top Sellers

Rank Fund Capital Flow
1
FHAM
Folger Hill Asset Management
New York
-$8.04M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.56M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$4.22M
4
PC
PointState Capital
New York
-$4.08M
5
EC
EcoR1 Capital
California
-$3.36M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
101
Cutler Group
California
$2K +$2.68K +100 New
LTFS
102
Ladenburg Thalmann Financial Services
Florida
$1K – – –
PHK
103
Point72 Hong Kong
Hong Kong
$1K +$295 +11 +30%
TRCT
104
Tower Research Capital (TRC)
New York
$1K +$724 +27 New
FHAM
105
Folger Hill Asset Management
New York
– -$8.04M -296,569 Closed
ACP
106
Acuta Capital Partners
California
– -$2.44M -90,000 Closed
KCM
107
Kennedy Capital Management
Missouri
– -$2.03M -74,962 Closed
GPCM
108
Granite Point Capital Management
Massachusetts
– -$1.78M -65,680 Closed
JGC
109
J. Goldman & Co
New York
– -$1.65M -60,975 Closed
SSA
110
Schonfeld Strategic Advisors
New York
– -$1.08M -40,000 Closed
Renaissance Technologies
111
Renaissance Technologies
New York
– -$784K -28,900 Closed
ARTA
112
A.R.T. Advisors
New York
– -$640K -23,600 Closed
SCA
113
Secor Capital Advisors
New York
– -$498K -18,370 Closed
HI
114
HBK Investments
Texas
– -$430K -15,867 Closed
Millennium Management
115
Millennium Management
New York
– -$409K -15,092 Closed
1 2 3 4
5

ACRS Hedge Fund Activity: Q3 2017 in Review

104 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2017, worth a combined $737M — up 6.1% from $694M a quarter earlier.

Fund positioning in ACRS was balanced in Q3 2017: 12 funds opened new positions, 12 closed out, 54 added to existing stakes and 24 trimmed.

The largest buyer was Deerfield Management, adding an estimated $32.2M. The largest seller was Folger Hill Asset Management, exiting entirely with an estimated $8.04M sold.

  • 104 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $737M of Aclaris Therapeutics stock for Q3 2017, up 6.1% quarter-over-quarter.
  • 12 funds opened new Aclaris Therapeutics positions in Q3 2017 and 12 closed out, a net change of 0 holders.
  • The largest Aclaris Therapeutics buyer in Q3 2017 was Deerfield Management, an estimated $32.2M added.
  • The largest Aclaris Therapeutics seller in Q3 2017 was Folger Hill Asset Management, an estimated $8.04M sold.

Based on aggregated 13F filings for Q3 2017.